NasdaqCM:AVTXBiotechs
Why Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Inclusion And Pipeline Progress
Avalo Therapeutics recently joined a wide range of Russell indices, including the Russell 3000, Russell 2000, Russell 2500, and related growth, value, small-cap, and micro-cap benchmarks, broadening its visibility across the U.S. equity landscape.
This sweeping index inclusion, alongside the appointment of veteran biopharma executive Ron Philip to the board and advancement of AVTX-010, highlights Avalo’s increasing presence in both capital markets and inflammatory disease drug...